DOCSLIB.ORG

Heterogeneous Induction of Major Histocompatibility Complex Class II Antigens on Corneal Endothelium by Lnterferon-7

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Heterogeneous Induction of Major Histocompatibility Complex Class II Antigens on Corneal Endothelium by Lnterferon-7 Investigative Ophthalmology & Visual Science, Vol. 32, No. 2, February 1991 Copyright © Association for Research in Vision and Ophthalmology Heterogeneous Induction of Major Histocompatibility Complex Class II Antigens on Corneal Endothelium by lnterferon-7 Beafnjs J. J. Foers,* Joosr J. von den Oord,t Alfons Billiau,}: Jo Von Damme,:}: and Luc Missotren* The expression and distribution of major histocompatibility complex (MHC) class II gene products, HLA-DR, HLA-DQ, and the HLA-DR invariant chain, were studied on flat mounts of human corneal endothelial cells (HCEC) after in vitro incubation of donor corneas with interferon-gamma (IFN-7), interleukin-1 (IL-1), and IL-6, using a sensitive immunoperoxidase technique with monoclonal anti- bodies. Control HCEC and endothelium treated with IL-1 or IL-6 completely lacked MHC class II antigens. After treatment with 50 U/ml, 100 U/ml, 500 U/ml, and 5000 U/ml of human IFN-7, a mosaic-like, patchy staining for all MHC class II products was observed: part of the HCEC showed membranous and/or cytoplasmic positivity; other endothelial cells were negative. In addition, a dose- dependent response to IFN-7 was observed: the proportion of cells expressing class II products rose with increasing doses of IFN-7. The induction of MHC class II antigen expression on HCEC by IFN-7 was completely inhibited by the addition of a neutralizing antibody directed to IFN-7 but not by IL-1/?. The significance of these findings with respect to corneal transplantation immunology is discussed. Invest Ophthalmol Vis Sci 32:341-345, 1991 The corneal endothelium is a major target in im- vestigated the effect of various doses of IFN-7, inter- mune rejection of corneal allografts. Although prod- leukin-1 (IL-1), and IL-6 on the induction of MHC ucts encoded by the major histocompatibility com- class II products in human corneal endothelial cells plex (MHC) play a key role in the initiation and (HCEC). Our results indicate that these cells are maintenance of rejection processes, the endothelial strikingly heterogeneous with respect to their re- cells of normal, freshly excised adult corneas are de- sponse to IFN-7. void of both MHC class I (or HLA-A, -B, and -C) and class II (or HLA-DR) antigens.1"3 Materials and Methods De novo appearance of MHC products has been Eight cadaver corneas were obtained from the reported in the endothelium of rejected corneal but- 8 4 5 Leuven Eye Bank. These corneas were excised from tons ' ; moreover, in vitro experiments have shown human eyes removed post mortem and stored for that MHC class II antigens can be induced on cul- various intervals in Minimum Essential Medium tured corneal endothelial cells by interferon-7 6 7 (Gibco, Paisly, Scotland) supplemented with 10% (IFN-7). ' However, neither the exact distribution of fetal calf serum (Gibco), 50 U/ml nystatin, 0.1 mg/ml the responding endothelial cells, nor the effect of amikacin, and 0.5 mg/ml ticarcillin. One additional other cytokines, are known as yet. Making use of the cornea was obtained from an eye that was operatively en face mounting technique of corneal endothelial removed because of primary malignant melanoma of cell-Descemet membrane complexes and a panel of the choroid. The viability of the HCEC layer was well-characterized monoclonal antibodies directed to evaluated by vital staining with Evans' blue. MHC class II products and related antigens, we in- Escherichia co//-derived human IFN-7 was cour- teously provided by Dr. W. W. Wolf (Bioferon, Lau- From the *Department of Ophthalmology, fDepartment of Pa- pheim, Germany). The IL-1/3 and IL-6 were derived thology, Laboratory of Histo- and Cytochemistry, tRega Institute from human peripheral blood leukocytes and were 9 for Medical Microbiology, University of Leuven, B-3000 Leuven, purified to homogeneity. D9D10 is a neutralizing Belgium. monoclonal antibody against human IFN-7.10 Submitted for publication: February 13, 1990; accepted Sep- The corneal fragments were incubated with cyto- tember 24, 1990. Reprint requests: B. J. J. Foets, Department of Ophthalmology, kines for 4 days at 37°C. In all experiments, a frag- University Hospital Sint-Rafael, Kapucijnenvoer 33, B-3000 Leu- ment that did not receive cytokines, served as a con- ven, Belgium. trol. Subsequently, the Descemet's membrane with 341 Downloaded from iovs.arvojournals.org on 09/27/2021 342 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE / February 1991 Vol. 32 the covering endothelial cell layer1' was gently peeled 1G-H). In general, the number of HCEC expressing off from the underlying stroma using a fine, monofil- the HLA-DR invariant or 7-chain outnumbered ament forceps. The samples of Descemet's mem- those expressing a- or /^-chains. brane-endothelium complex were mounted on albu- To exclude nonspecific induction of MHC class II min-coated slides, dried at room temperature, and products by contaminants in the recombinant IFN-7, fixed for 10 min in absolute acetone. the effect of addition of a neutralizing monoclonal The MHC class II products and related antigens antibody D9D10 directed to IFN-7 was studied. For were detected with a three-step avidin-biotin-peroxi- this purpose, small parts of two cadaver corneas were dase complex (ABC) method. Rehydrated slides were incubated in standard culture medium, in medium incubated with the following monoclonal antibodies: supplemented with IFN-7 (100 or 500 U/ml), in me- TAL1B5 (Imperial Cancer Research Fund, London, dium containing the same doses of IFN-7 to which UK) and L243 (Becton-Dickinson, Mechelen, Bel- anti-IFN-7 antibody was added in excess before the gium), directed to the monomorphic part of HLA- time of incubation, or in medium containing the an- DR a- and /3-chains respectively; LN3 (Biotest, Brus- tibody alone. sels, Belgium) and CR3/43 (DY Mason, Oxford, The induction of MHC class II product expression UK), directed to nonpolymorphic parts of HLA-DR was completely inhibited by the addition of antibody, antigens; LN2 (Biotest), detecting the MHC class II directed to IFN-7 (Fig. 2A). Treatment of cornea invariant or 7-chain; Tu 22 (Biotest) and Leu 10 fragments with neutralizing antibody alone had no (Becton-Dickinson), directed to HLA-DQ antigens. effect on MHC class II expression. The second and third step consisted of biotinylated To study the effect of IL-1 on the inductive effect of rabbit anti-mouse immunoglobulins and peroxidase- IFN-7,12 fragments of one cadaver cornea were incu- conjugated ABC, respectively (both purchased from bated in standard culture medium, in medium sup- Dakopatts, Copenhagen, Denmark). All incubations plemented with 100 U/ml IFN-7, or in medium con- were done for 30 min at room temperature and fol- taining a mixture of 100 U/ml IFN-7 and 100 U/ml lowed by a wash in three changes of phosphate-buff- IL-1 per ml medium. Incubation of corneal samples ered saline, pH 7.2, for 15 min. The reaction product with a mixture of IL-1 and IFN-7 did not alter the was developed by addition of 3-amino-9-ethylcarba- IFN-7-induced MHC class II antigen expression zole and H2O2. (Fig. 2B). Results Discussion Parts taken from three cadaver corneas and from Using in situ immunohistochemical techniques one fresh cornea were placed in separate bottles con- and a panel of monoclonal antibodies, we showed taining 5 ml of culture medium to which IFN-7 had that IFN-7 is capable of inducing de novo expression been added in doses of 5000, 500, 100, or 50 U/ml. of MHC class II products on HCEC. Class II MHC Pieces from from other cadaver corneas were handled products13 can be divided into three major subsets of similarly, but they received IL-1/3 in doses of 50, 5, or products, called HLA-DR, HLA-DQ (or -DC), and 0.5 U/ml or IL-6 in doses of 300, 30, or 3 U/ml. HLA-DP (or -SB). The HLA-DR antigens were ini- Control HCEC, incubated in culture medium de- tially believed to occur only on cells involved in im- void of cytokines, did not react with any of the mono- mune responses, ie, B lymphocytes, activated T cells, clonal antibodies used (Fig. 1A). Similarly, neither monocytes/macrophages, dendritic cells, and vascu- IL-1 nor IL-6 induced MHC class II product expres- lar endothelial cells. In the last few years, however, an sion. Human IFN-7, on the other hand, induced de increasing number of nonlymphoid cell types has novo expression of MHC class II products and the been shown to display HLA-DR molecules either invariant or 7-chain of HLA-DR on HCEC in a constitutively14 or after appropriate stimulation by dose-dependent fashion. After treatment with 50 lymphokines.15 The HLA-DP and -DQ antigens, on U/ml, a mosaic-like, patchy staining was caused by the other hand, are more restricted in distribution16 scattered endothelial cells that expressed HLA-DR a- and are less easily induced by lymphokines. and jQ-chains (Fig. IB) and HLA-DQ chains on their In the normal human cornea, MHC class II prod- cell membranes and/or in the cytoplasm. With in- ucts are restricted to epithelial dendritic cells, occa- creasing doses of IFN-7, more endothelial cells ex- sional stromal spindle cells, and vascular endothelial pressed MHC class II products (Figs. 1C-1F), and cells in the limbus.1"3 However, in the course of after treatment with doses of 5000 U/ml, virtually all chronic infections4'7 or during allograft rejection,4-5 HCEC were found to be immunoreactive (Figs. "aberrant" HLA-DR expression may be found on the Downloaded from iovs.arvojournals.org on 09/27/2021 No.
Load more

Recommended publications
  • High-Allelic Variability in HLA-C Mrna Expression: Association with HLA-Extended Haplotypes
    Genes and Immunity (2014) 15, 176–181 & 2014 Macmillan Publishers Limited All rights reserved 1466-4879/14 www.nature.com/gene ORIGINAL ARTICLE High-allelic variability in HLA-C mRNA expression: association with HLA-extended haplotypes F Bettens1,2, L Brunet1,2 and J-M Tiercy1 Human leukocyte antigen (HLA)-C is a clinically relevant transplantation antigen in unrelated hematopoietic stem cell and cord blood transplantation. Furthermore, HLA-C antigens, as ligands for killer immunoglobulin-like receptors expressed on natural killer cells, have a central role in HIV control. Several studies have reported significant correlations between HLA-C mRNA and cell surface expression with polymorphisms in the 50- and 30-regions of the HLA-C locus. We determined HLA-C mRNA in blood donors by using locus as well as allele-specific real-time–PCR and focused the analysis on HLA-extended haplotypes. High inter-individual variability of mRNA expression was disclosed. A lower inter-individual variability for C*07:01 but a higher variability for C*06:02, C*04:01 and C*03:04 alleles were detected. The previously reported associations between HLA-C cell surface expression and À 32 kb/ À 35 kb single nucleotide polymorphisms were not confirmed. Related and unrelated individuals sharing the same two A-B-C-DRB1 or B-C haplotypes show strikingly similar levels of HLA-C mRNA expression in each of the different haplotypic combinations tested. Altogether, our results suggest that HLA-C expression levels best correlate with the extended HLA haplotype rather than with the allotype or with polymorphisms in the 50-region of the HLA-C locus.
    [Show full text]
  • HLA-DPB1 Gene Major Histocompatibility Complex, Class II, DP Beta 1
    HLA-DPB1 gene major histocompatibility complex, class II, DP beta 1 Normal Function The HLA-DPB1 gene provides instructions for making a protein that plays a critical role in the immune system. The HLA-DPB1 gene is part of a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria. The HLA complex is the human version of the major histocompatibility complex (MHC), a gene family that occurs in many species. The HLA-DPB1 gene belongs to a group of MHC genes called MHC class II. MHC class II genes provide instructions for making proteins that are present on the surface of certain immune system cells. These proteins attach to protein fragments (peptides) outside the cell. MHC class II proteins display these peptides to the immune system. If the immune system recognizes the peptides as foreign (such as viral or bacterial peptides), it triggers a response to attack the invading viruses or bacteria. The protein produced from the HLA-DPB1 gene attaches (binds) to the protein produced from another MHC class II gene, HLA-DPA1. Together, they form a functional protein complex called an antigen-binding DPab heterodimer. This complex displays foreign peptides to the immune system to trigger the body's immune response. Each MHC class II gene has many possible variations, allowing the immune system to react to a wide range of foreign invaders. Researchers have identified hundreds of different versions (alleles) of the HLA-DPB1 gene, each of which is given a particular number (such as HLA-DPB1*03:01).
    [Show full text]
  • HLA on Chromosome 6: the Story Gets Longer and Longer Leslie J
    COMMENTARY HLA on Chromosome 6: The Story Gets Longer and Longer Leslie J. Raffel,1 Janelle A. Noble,2 and Jerome I. Rotter1 within the MHC has played a substantial role in allowing disease linkages and associations to be detected. The early ver the past three decades, substantial progress studies that reported associations with HLA-B8 and -B15 has been made in understanding the genetic used remarkably small numbers of cases and controls basis for diabetes. One of the important first relative to the hundreds to thousands considered neces- Osteps that allowed this progress to occur was sary in current studies (4–6). Had it not been for the realizing that diabetes is heterogeneous, and, therefore, strong LD, those initial studies would have been unlikely separation of clinically distinct forms of the disorder (i.e., to yield positive results. Yet, at the same time, this LD has type 1 vs. type 2 diabetes) improves the ability to detect also created challenges in accomplishing the next step, genetic associations. The key points that allowed type 1 that of identification of the specific genes that are respon- diabetes to be separated from type 2 diabetes included sible for disease susceptibility. The fact that researchers realization of the clinical differences (typically childhood have spent Ͼ30 years trying to elucidate all of the loci onset, thin, ketosis-prone versus adult onset, obese, non- responsible for type 1 diabetes susceptibility in the HLA ketosis prone); family and twin studies that demonstrated region underscores the complexity
    [Show full text]
  • A Second Lineage of Mammalian Major Histocompatibility Complex Class I Genes SEIAMAK BAHRAM*, MAUREEN BRESNAHAN*, DANIEL E
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 6259-6263, July 1994 Immunology A second lineage of mammalian major histocompatibility complex class I genes SEIAMAK BAHRAM*, MAUREEN BRESNAHAN*, DANIEL E. GERAGHTYt, AND THOMAS SPIES* *Diision of Tumor Virology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115; and tHuman Immunogenetics Program, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104 Communicated by Sherman M. Weissman, January 3, 1994 ABSTRACT Major sctibit complex (MHC) polymorphic antigen-presenting molecules (2). The physio- class I genes tpically encode polymorphic peptide-binding logical roles of HLA-E and -F are uncertain (14, 15), but chains which are ubi ly expressed and mediate the HLA-G may have a specific function at the maternal-fetal recognition of intr rtigens by cytotoxic T cells. They interface (16). In addition, the MHC contains a number of constte diverse gene fme in different species and include class I pseudogenes and gene fragments (17); however, all of the numerous cd n acal genes in the mouse H-2 the human class I sequences share close relationships indi- coplex, of which some have been adapted to variously mod- cating their common origin from a typical class I gene. ified hmctions. We have identified a d nt family of five In this report, we describe a family of sequencest in the related sequenes in the human MHC whicb are distntly human MHC which are highly divergent from al of the homologous to dass I i. These MIC genes (MHC class I known MHC class I chains and have presumably been chain-related genes) evolved in parallel with the human class I derived early in the evolution of mammalian class I genes.
    [Show full text]
  • Histocompatibility Antigens
    HISTOCOMPATIBILITY ANTIGENS 2 CRAIG 1. TAYLOR 1 and PHILIP A. DYER Cambridge and Manchester Keratoplasty is a well-established method for the are similar for corneal grafts and other forms of treatment of irreversible corneal opacity, ocular allotransplantation.12,13 disease and injury. For primary transplants in patients with avascular corneal beds (usually asso­ HLA SYSTEM ciated with keratoconus) success rates are relatively The dominant antigenic stimulus for allograft rejec­ high when compared with other forms of organ tion and antibody production is the MHC (major transplantation, with 90-95% 1 year graft survival. I histocompatibility complex). In humans this is known This is achieved even in the absence of intensive as the HLA (human leucocyte antigen) system, The systemic immunosuppression, reflecting the view that products of the MHC genes control T cell antigen the avascular cornea enjoys some degree of recognition. Evidence that HLA is the human MHC 'immunological privilege'. However, even in this came from early kidney transplants performed using situation some 10% of patients undergo a rejection related donors. Graft survival was shown to correlate episode of which up to half may progress to with the number of HLA haplotypes shared between irreversible clouding and graft failure?,3 the donor and recipient, with 90% 1 year graft In contrast, for patients with a vascularised corneal survival between HLA-identical siblings. The 10% of bed a different picture emerges, with 35% graft loss transplant failures despite immunosuppression, is in the first year following transplantation.4 This thought to represent multiple minor histocompat­ ibility antigen differences. situation is more closely analogous to solid organ The HLA system is a complex mUltigene family transplants where vascularisation enables access of consisting of more than 10 loci coded for on the short the host immune system, with a concomitant arm of chromosome 6.
    [Show full text]
  • Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer
    Author Manuscript Published OnlineFirst on November 21, 2018; DOI: 10.1158/1078-0432.CCR-18-3200 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer Running Title: Biological Consequences of MHC-II Expression by Tumor Cells Margaret L. Axelrod1,2, Rebecca S. Cook2,3,4,5, Douglas B. Johnson1,5, and Justin M. Balko*1,2,5 Affiliations: Department of Medicine, Vanderbilt University Medical Center1; Cancer Biology Graduate Program2, Department of Cell and Developmental Biology3, and Department of Biomedical Engineering4, Vanderbilt University, and the Vanderbilt-Ingram Cancer Center5, Nashville, TN 37232 Acknowledgments: This article is supported by the U.S. Department of Defense (BC170037; J. M. Balko) and the National Institute of General Medical Sciences (T32GM007347; M. L. Axelrod). Conflicts and Disclosures: D. B. Johnson reports receiving commercial research grants from Bristol-Myers Squibb and Incyte, is a consultant/advisory board member for Array, Bristol-Myers Squibb, Genoptix, Merck, Incyte, and Novartis, and is inventor on a provisional patent on the use of MHC-II as a biomarker of immunotherapy response. J. M. Balko is a consultant/advisory board member for Novartis, reports receiving commercial research grants from Incyte, Bristol- Myers Squibb, and Genentech, and is inventor on a provisional patent on the use of MHC-II as a biomarker of immunotherapy response and a patent on HLADR as a biomarker for ICI response. No potential conflicts of interest were disclosed by the other authors. Downloaded from clincancerres.aacrjournals.org on October 2, 2021.
    [Show full text]
  • Orientation of Loci Within the Human Major Histocompatibility Complex by Chromosomal in Situ Hybridization (Human Leukocyte Antigen/Gene Mapping) CYNTHIA C
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 2816-2820, May 1984 Genetics Orientation of loci within the human major histocompatibility complex by chromosomal in situ hybridization (human leukocyte antigen/gene mapping) CYNTHIA C. MORTON*t, ILAN R. KIRSCHt, WALTER E. NANCE*, GLEN A. EVANS§, ALAN J. KORMAN¶, AND JACK L. STROMINGER¶ *Department of Human Genetics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298; tNational Cancer Institute, Navy Medical Oncology Branch, The National Naval Medical Center, Building 1, Room 415, Bethesda, MD 20814; §The Cancer Biology Laboratory, The Salk Institute, San Diego, CA 92138; and ¶Fairchild Biochemistry Building, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138 Contributed by Jack L. Strominger, December 29, 1983 ABSTRACT We have determined the localization and ori- with closely linked markers such as glyoxylase 1 (GLO 1) entation of two genetic probes within the human major histo- have permitted inferences to be drawn about the order and compatibility complex by chromosomal in situ hybridization. map distances between marker loci on the proximal portion Our data indicate that a cloned genomic probe cross-hybridiz- of the short arm of chromosome 6, as follows: GLO 1-4 ing to HLA-A, -B, and -C heavy chain loci is homologous to centimorgans (cM)-HLA-DR-0.3 cM-BF, C4B, C4A, sequences located on chromosome 6 at band p21.3 while a sub- C2-0.7 cM-HLA-B-0.1 cM-HLA-C-0.7 cM-HLA-A clone of the genomic HLA-DR a-chain gene corresponding to (16-18). the nonpolymorphic p34 protein is homologous to sequences in Improvements in chromosomal in situ hybridization have band 6p21.1.
    [Show full text]
  • Major Histocompatibility Antigens and Antigen-Processing Molecules in Uveal Melanoma1
    Vol. 9, 4159–4164, September 15, 2003 Clinical Cancer Research 4159 Major Histocompatibility Antigens and Antigen-processing Molecules in Uveal Melanoma1 Subramanian Krishnakumar, Dhiraj Abhyankar, tigens and the APM was seen in nonepithelioid cell melano- Amirtha Lakshmi Sundaram, mas. There was no correlation with largest tumor diameter. Conclusions: Our data suggest decreased expression of Vaijayanthi Pushparaj, HLA, and APM are seen in uveal melanomas with no ex- Mahesh Palanivelu Shanmugam, and trascleral extension and in nonepithelioid cell melanomas. 2 Jyotirmay Biswas Decreased expression of APM may contribute to decreased Department of Ocular Pathology [S. K., A. L. S., V. P., J. B.] and HLA class I antigen expression. Ocular Oncology [M. P. S.], Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, 600 600, India, and Department of Immunology, Roswell Park Cancer Institute, Buffalo, INTRODUCTION New York 142631 [D. A.] Uveal melanoma is the commonest primary intraocular tumor in Caucasian adults, with an incidence rate of 0.7/100,000. The average survival rate after the diagnosis of ABSTRACT metastatic disease, usually in the liver, is between 2 and 7 Purpose: Malignant transformation of cells is fre- months. No effective treatment for metastatic disease is yet quently associated with abnormalities in the human leuko- available (1). The therapy of uveal melanoma remains problem- cyte antigen (HLA) expression. These abnormalities may atic because of the high rate of metastatic dissemination, irre- play a role in the clinical course of the disease, because HLA spective of the success of treatment of the primary tumor. When antigens mediate interactions of tumor cells with T cells and metastatic disease is diagnosed, patient survival is usually Ͻ1 natural killer cells.
    [Show full text]
  • HLA – Basics (Or How to Recognize “Self”)
    HLA – Basics (or how to recognize “self”) Directors’ Affairs Committee plus others (with our gratitude) Overview • Some Definitions – MHC and HLA – Class I and Class II – Nomenclature • Class II extended haplotypes • HLA Typing Technology • HLA Immunogenicity • Solid Phase Antibody detection methods • HLA and Disease Associations • HLA and Pharmacogenetics • Review 2 Human Leukocyte Antigens Polymorphism slide-new alleles each year 3 Major Histocompatibility Complex (MHC) • MHC in humans is named “Human Leukocyte Antigens” (HLA) as they were first defined on the surface of peripheral blood leukocytes • HLA Class I in humans is found on virtually all nucleated cells and platelets • HLA Class II (constitutive expression) is restricted to specialized cells of the immune system (macrophages, B cells, etc.) • HLA genes are highly polymorphic 4 HLA Protein Structure CD8 Tcell cytosol • Class I is heterodimeric with a polymorphic alpha chain and a plasma membrane common beta-2 microglobulin – Alpha chain is composed of 3 TCR extra-cellular domains ( α1, α2, and α3) – α1 and α2 form a groove like structure with a floor of β α2 α1 pleated sheets and ridges of α helices CD8 – presents peptides derived from α3 β2 m internal cellular proteins to the T cell receptor of CD8 T cells. plasma membrane – involved in the immune response cytosol against intra-cellular parasites, Antigen Presenting Cell viruses and cancer 5 HLA Class I Molecule Influenza M1 A view down the peptide groove of an HLA-A2 ααα1 domain molecule ααα2 domain βββ2 microglobulin ααα3
    [Show full text]
  • Histocompatibility Y Antigen Compatibility and Allograft Rejection
    Histocompatibility Y KENJI INOUE, SHIRO AMANO, TETSURO OSHIKA, TADAHIKO TSURU antigen compatibility and allograft rejection in corneal transplantation Abstract Rejection is triggered when the host lymphocytes recognise the major and minor Purpose To assess the effects of histocompatibility antigens expressed by cells of histocompatibility Y (H-Y) antigen matching the corneal grafts. In humans, the effects of on the rate of corneal allograft rejection after matching of the major histocompatibility penetrating keratoplasty (PKP). complex (MHC) in corneal transplantation are Methods We retrospectively investigated the subject to controversy?-9 Some previous studies graft survival rate and rejection-free graft have reported that the matching of HLA- and survival rate after PKP in 396 eyes. The A-B antigens decreases the rate of graft compatible combinations of H-Y antigen . reJectIOn,. 37- wh ere as ot h ers reported that the included male donors and male recipients (n = matching of HLA-A, -B and -DR antigens does 135), female donors and male recipients (n = not decrease the rate of allograft rejection.8,9 107), and female donors and female recipients Histocompatibility Y (H-Y) antigen is a male­ (n = 60). Incompatible combination was from specific minor histocompatibility antigen and male donors and female recipients (n = 94). was originally found as a transplantation The eyes were classified into two groups - antigen by Eichwald and Slimser in 1955.10 They high-risk (168 eyes) and low-risk (228 eyes) - found that skin grafts from male donors could depending on the degree of vascularisation in K. Inoue be rejected by female recipients from certain the recipient corneas or a history of previous Department of strains of inbred mice.lO The term H-Y antigen Ophthalmology allograft rejection.
    [Show full text]
  • Ncomms8146.Pdf
    ARTICLE Received 8 Feb 2015 | Accepted 7 Apr 2015 | Published 21 May 2015 DOI: 10.1038/ncomms8146 OPEN Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1 Adrian Cortes1,SaraL.Pulit2,PaulJ.Leo1, Jenny J. Pointon3, Philip C. Robinson1, Michael H. Weisman4,MichaelWard5, Lianne S. Gensler6, Xiaodong Zhou7, Henri-Jean Garchon8,9, Gilles Chiocchia8, Johannes Nossent10,11,BenedicteA.Lie12,13, Øystein Førre14, Jaakko Tuomilehto15,16,17, Kari Laiho18, Linda A. Bradbury1, Dirk Elewaut19,20, Ruben Burgos-Vargas21, Simon Stebbings22, Louise Appleton3,ClaireFarrah3, Jonathan Lau3,NigilHaroon23, Juan Mulero24, Francisco J. Blanco25, Miguel A. Gonzalez-Gay26,C.Lopez-Larrea27,28,PaulBowness3, Karl Gaffney29, Hill Gaston30,DafnaD.Gladman31,32,33, Proton Rahman34, Walter P. Maksymowych35,J.BartA.Crusius36, Irene E. van der Horst-Bruinsma37, Raphael Valle-On˜ate38, Consuelo Romero-Sa´nchez38, Inger Myrnes Hansen39, Fernando M. Pimentel-Santos40, Robert D. Inman23,JavierMartin41, Maxime Breban8,42,BryanPaulWordsworth3, John D. Reveille7, David M. Evans1,43,44,PaulI.W.deBakker2,45 & Matthew A. Brown1 Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains elusive. To better understand the genetic basis of the MHC susceptibility loci, we genotyped 7,264 MHC SNPs in 22,647 AS cases and controls of European descent. We impute SNPs, classical HLA alleles and amino-acid residues within HLA proteins, and tested these for association to AS status. Here we show that in addition to effects due to HLA-B*27 alleles, several other HLA-B alleles also affect susceptibility.
    [Show full text]
  • Significance of The
    CHAPTERCHAPTER 7 7 SignificanceSignificance ofof thethe MHCMHC MajorMajor HistocompatibilityHistocompatibility Complex Complex (MHC)(MHC) WhatWhat isis MHC?MHC? rolerole inin immuneimmune responseresponse ––HLAHLA rolerole inin organorgan transplantationtransplantation – H-2 – H-2 rolerole inin predispositionpredisposition toto diseasedisease ––MinorMinor histocompatibilityhistocompatibility antigensantigens ––PeterPeter GorerGorer & & GeorgeGeorge SneellSneell (1940) (1940) - MHC molecules were initially discovered during studies Chromosome 17 aimed at understanding the molecules responsible for rejection of transplanted tissues . - Hence the name “Major Histocompatibility Complex ” L (MHC). - The term “Major Histocompatibility Complex” actually refers to a region of the genome that encodes a number of genes (hence Complex) that play an important (hence Chromosome 6 Major) role in tissue transplantation (hence Histocompatibility). - The term “MHC molecule” or “MHC antigen” refers to a molecule encoded by a gene within this region. In humans: In the Mouse: Class I = A, B and C (also called HLA-A, HLA-B and HLA-C) Class I = K, D and L molecules (also called - Ag (peptide) presentation to CD8+ cells H-2D, H-2K and H-2L) Class II = DP, DQ and DR (also called Class II = A and E (also called I-A and I-E) HLA-DP, HLA-DQ and HLA-DR) - Ag (peptide) presentation to CD4+ cells Class III = Complement proteins, Tumor necrosis factor (TNFs)-α, β Class III = Complement proteins, Tumor necrosis factor (TNFs)-α, β 1 MHC- Polimorphism PolymorphismPolymorphism
    [Show full text]